Abstract
Purpose Examine the effect of AMPK activation in addition to OCT2 competitive blockage through metformin concomitant treatment on the incidence rate of nephrotoxicity in adult head and neck cancer patients treated with cisplatin-based chemoradiation.
Methods A single center retrospective three to one controlled study in HNSCC patients treated at a single academic health center between January 1st 2015 to December 31st 2021. Patients treated with cisplatin based chemoradiation regimen at a dose of either 40 mg/m2 weekly, or 100 mg/m2 every 3 weeks for a total of 7 weeks were identified and were divided into two cohorts; Cohort A with patients who received concomitant metformin therapy, where concomitant is defined as taken prior to the time of cisplatin start and continued during treatment. And cohort B with a control group of patients who did not receive metformin during cisplatin treatment.
Results 18 patients were enrolled retrospectively in cohort A and 54 in cohort B. Our data shows a lower incidence of nephrotoxicity than reported in historical controls. However, no statistically significant differences were identified in direct comparison between the two cohorts.
Conclusion Our data reaffirms the higher risk of nephrotoxicity for patients on Q3weeks regimen compared to weekly regimen, however, we were unable to show a statistically significant effect in direct comparison between the cohorts due to sample size limitation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Michigan Medicine waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
dellayan{at}med.umich.edu
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data Availability
All deidentified data produced in the present study are available upon reasonable request to the author after IRB approval of the request
